SCHEMBL5193159

SCHEMBL5193159

Nc1cc(OCc2ccccc2)cc(CC=O)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.47
▸ CYP1A1 P04798 1/20 0.47
▸ CYP19A1 P11511 1/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ LMNA P02545 1/20 0.44
▸ PTGS1 P23219 1/20 0.44
▸ SLC6A2 P23975 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ PTGS2 P35354 1/20 0.44
▸ SLC6A3 Q01959 1/20 0.44
▸ HIF1A Q16665 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ MAOB P27338 6/20 0.43
▸ MAOA P21397 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5024079 0.80 BACE1 (0.46) MEN1KMT2AMAOBMAOAMAPT
SCHEMBL3643405 0.79 MAOB (0.54) CYP1A2LMNAPTGS1SLC6A2CYP2C19
SCHEMBL28102855 0.78 CYP1A2 (0.44) CYP1A2CYP1A1CYP19A1MEN1KMT2A
SCHEMBL3641442 0.77 MAOB (0.59) CYP1A2LMNAPTGS1SLC6A2CYP2C19
SCHEMBL6943499 0.76 MEN1 (0.59) CYP1A2CYP1A1CYP19A1MEN1KMT2A
SCHEMBL23817091 0.76 MEN1 (0.52) CYP1A2MEN1KMT2AMAOBMAOA
SCHEMBL4012665 0.76 CYP1A2 (0.50) CYP1A2CYP1A1CYP19A1MEN1KMT2A
SCHEMBL28769206 0.75 CYP1A2 (0.49) CYP1A2CYP1A1CYP19A1MEN1KMT2A
SCHEMBL6203294 0.74 MAOB (0.51) CYP1A2LMNAPTGS1SLC6A2CYP2C19
SCHEMBL561095 0.74 MAOB (0.62) CYP1A2CYP1A1CYP19A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1853596-A1 NOVEL, LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY DISEASES Boehringer Ingelheim International GmbH (DE) 2007-11-14 — — EP disclosed
EP-1809236-A1 INHALATION POWDER FORMULATIONS CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-07-25 — — EP disclosed
EP-1789405-A1 NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-30 — — EP disclosed
EP-1789394-A1 HYDROXY-SUBSTITUTED BENZO-CONDENSED HETEROCYCLES FOR USE AS BETA AGONISTS IN THE TREATMENT OF RESPIRATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-30 — — EP disclosed
WO-2006087315-A1 NOVEL, LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-08-24 — — WO disclosed
WO-2005110359-A1 INHALATION POWDER FORMULATIONS CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-24 — — WO disclosed
WO-2005110990-A1 HYDROXY-SUBSTITUTED BENZO-CONDENSED HETEROCYCLES FOR USE AS BETA AGONISTS IN THE TREATMENT OF RESPIRATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-24 — — WO disclosed
WO-2005111005-A1 NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-24 — — WO disclosed
Send feedback